Fidelity Select Biotechnology Portfolio Gross Profit

Fidelity Select Biotechnology Portfolio posts a gross profit of $43M as of October 2023. That compares with $9.4M in the prior-year period — up 356.4% year over year. That is below the sector sector average of $6.6T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Fidelity Select Biotechnology Portfolio's gross profit was $9.4M. The latest reading is $43M — a 356.4% year-over-year increase (period ending October 2023). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a gross profit near $6.6T is typical. Fidelity Select Biotechnology Portfolio's $43M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of Fidelity Select Biotechnology Portfolio's financial statement story. At $43M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for FBIOX's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $6.6T), and (3) consistency with growth and profitability. This page covers the first two; Fidelity Select Biotechnology Portfolio's other metric pages and overview cover the third.